Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes

被引:123
作者
Erpenbeck, VJ
Hohlfeld, JM
Volkmann, B
Hagenberg, A
Geldmacher, H
Braun, A
Krug, N
机构
[1] Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Resp Med, D-3000 Hannover, Germany
关键词
atopy; asthma; IL-9; segmental allergen challenge; real-time PCR;
D O I
10.1067/mai.2003.1485
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: IL-9 is a T(H)2 cell-derived cytokine that might be involved in the pathophysiology of allergic diseases. Little is known about its expression and release during the allergic response in the human lung. Objective: The expression of IL-9 was measured in 10 atopic subjects with mild asthma and 5 nonatopic healthy control subjects at baseline and 24 hours after segmental sham and allergen challenge. Methods: IL-9 protein was measured in bronchoalveolar lavage (BAL) fluid by means of ELISA and detected within the BAL cells by means of immunocytochemistry. Furthermore, IL9 mRNA expression of BAL cells was detected by means of real-time PCR. Results: Although only low or undetectable amounts of IL9 mRNA and IL-9 protein were present in nonatopic control subjects and atopic asthmatic patients at baseline, there was an increase after segmental allergen challenge in the atopic subjects. Lymphocytes were identified as major cellular sources of IL-9 production by means of immunocytochemistry. Furthermore. IL-9 protein and IL9 mRNA expression correlated with eosinophil numbers in BAL fluid. Conclusions: These findings demonstrate that IL-9 is specifically upregulated after local allergen challenge in the lungs of atopic asthmatic patients. Lymphocytes are the major cellular source of IL-9. The increased expression and its correlation with eosinophil numbers suggest a potential role for IL-9 in the late phase of the allergic response. (J Allergy Clin Immunol 2003:111:1319-27.).
引用
收藏
页码:1319 / 1327
页数:9
相关论文
共 28 条
[1]   Interleukin-9 receptor expression in asthmatic airways in vivo [J].
Bhathena, PR ;
Comhair, SAA ;
Holroyd, KJ ;
Erzurum, SC .
LUNG, 2000, 178 (03) :149-160
[2]   Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model [J].
Cheng, G ;
Arima, M ;
Honda, K ;
Hirata, H ;
Eda, F ;
Yoshida, N ;
Fukushima, F ;
Ishii, Y ;
Fukuda, T .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) :409-416
[3]  
Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO
[4]  
2-S
[5]   INTERLEUKIN-9 POTENTIATES THE INTERLEUKIN-4-INDUCED IMMUNOGLOBULIN (IGG, IGM AND IGE) PRODUCTION BY NORMAL HUMAN B-LYMPHOCYTES [J].
DUGAS, B ;
RENAULD, JC ;
PENE, J ;
BONNEFOY, JY ;
PETIFRERE, C ;
BRAQUET, P ;
BOUSQUET, J ;
VANSNICK, J ;
MENCIAHUERTA, JM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (07) :1687-1692
[6]   IL-9 expression by human eosinophils:: Regulation by IL-1β and TNF-α [J].
Gounni, AS ;
Nutku, E ;
Koussih, L ;
Aris, F ;
Louahed, J ;
Levitt, RC ;
Nicolaides, NC ;
Hamid, Q .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (03) :460-466
[7]  
Gounni AS, 2000, BLOOD, V96, P2163
[8]  
HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147
[9]   MAST-CELL GROWTH-ENHANCING ACTIVITY (MEA) IS STRUCTURALLY RELATED AND FUNCTIONALLY IDENTICAL TO THE NOVEL MOUSE T-CELL GROWTH FACTOR-P40 TCGFIII (INTERLEUKIN-9) [J].
HULTNER, L ;
DRUEZ, C ;
MOELLER, J ;
UYTTENHOVE, C ;
SCHMITT, E ;
RUDE, E ;
DORMER, P ;
VANSNICK, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (06) :1413-1416
[10]   Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children [J].
Jenmalm, MC ;
Van Snick, J ;
Cormont, E ;
Salman, B .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (10) :1528-1535